Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective cohort study to evaluate ultrasonographic efficacy of biologic and targeted synthetic disease‐modifying antirheumatic drug therapy in rheumatoid arthritis patients

Next Previous
Search
Trial Profile

A prospective cohort study to evaluate ultrasonographic efficacy of biologic and targeted synthetic disease‐modifying antirheumatic drug therapy in rheumatoid arthritis patients

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Tocilizumab (Primary) ; Tofacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use

Most Recent Events

  • 29 Jun 2020 New trial record
  • 06 Jun 2020 Results of patients with active RA who have introduced treatment with abatacept and had finished the first 12-month observation (n=43) period, presented at the 21st Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top